View Past PerformanceImmutep 대차대조표 건전성재무 건전성 기준 점검 6/6Immutep 의 총 주주 지분은 A$98.9M 이고 총 부채는 A$0.0, 이는 부채 대 자기자본 비율을 0% 로 가져옵니다. 총자산과 총부채는 각각 A$147.2M 및 A$48.3M 입니다.핵심 정보0%부채/자본 비율AU$0부채이자보상배율n/a현금AU$99.13m자본AU$98.90m총부채AU$48.30m총자산AU$147.20m최근 재무 건전성 업데이트업데이트 없음모든 업데이트 보기Recent updatesImmutep Limited Reports Progress From Phase I Study Of LAG-3 Agonist IMP761 For Autoimmune DiseasesMar 19Immutep Limited Discontinues TACTI-004 Phase III Study in First Line NSCLC Following Futility AnalysisMar 13Immutep Limited Achieves 50% Enrolment in Global TACTI-004 (KeyNOTE-F91) Phase III Trial in 1L NSCLCFeb 06Immutep Limited Announces Strong Operational Progress in Global TACTI-004 (KEYNOTE-F91) Phase III and Enrolment Continues At Robust PaceDec 17Immutep Limited to Present New Data from AIPAC-003 Phase II at the 2025 San Antonio Breast Cancer SymposiumDec 02Immutep Limited Announces Positive Data from the EFTISARC-NEO TrialNov 13Primary Endpoint Met in EFTISARC-NEO Phase II Evaluating Neoadjuvant Efti in Soft Tissue Sarcoma and Data Presented At ESMO Congress 2025Oct 21Immutep Limited, Annual General Meeting, Nov 27, 2025Oct 15Immutep Limited Announces Successful Completion of FDA Project Optimus RequirementsOct 14Immutep Limited Announces Update for Tacti-004 (Keynote-F91) Phase Iii Trial in First Line Non-Small Cell Lung CancerOct 09Immutep Limited Announces Data from EFTISARC-NEO Phase II Evaluating Neoadjuvant Efti in Soft Tissue Sarcoma Accepted for Oral Presentation At CTOS 2025Sep 08Immutep Limited Receives Positive Feedback from FDA on Late-Stage Clinical Development of Eftilagimod Alfa in Head and Neck Cancer with CPSAug 05Immutep Limited to Present Pivotal TACTI-004 Trial in Progress Poster at the 2025 World Conference on Lung CancerJul 29Immutep Limited Announces Positive Update from Phase I Study of IMP761, A First-In-Class LAG-3 Agonist Antibody for Autoimmune DiseasesJun 24Immutep Limited's Efti with Radiotherapy & KEYTRUDA®? (Pembrolizumab) Meets Primary Endpoint in Phase Ii for Soft Tissue SarcomaMay 27Immutep Limited's Efti with Keytruda (Pembrolizumab) & Chemotherapy Achieves High Response Rates in First-Line Non-Small Cell Lung CancerMay 15Immutep Limited's Efti in Combination with KEYTRUDA®? (pembrolizumab) Drives Strong Overall Survival in Head and Neck Cancer with CPSMay 06Immutep Limited Announces First Patient Dosed in TACTI-004 Phase III Trial in First Line Non-Small Cell Lung CancerMar 25Immutep Limited to Present Pivotal TACTI-004 Trial in Progress Poster At the European Lung Cancer Congress 2025Mar 20Immutep Limited Announces Patient Enrolment Complete in the Investigator-Initiated EFTISARC-NEO TrialJan 22Immutep Announces Initial Safety Data from First-in-Human Phase I Trial Evaluating IMP761Dec 18Immutep Limited and Monash University Announce First Publication Detailing How Human LAG-3 Binds to MHC Class IIDec 16Immutep Limited Reports Promising New Data in Head and Neck Cancer At ESMO Immuno-Oncology 2024Dec 12Immutep Limited Announces Initiation of TACTI-004 Phase III Trial in First Line Non-Small Cell Lung CancerDec 10Immutep Limited, Annual General Meeting, Nov 22, 2024Oct 10Immutep Limited Announces Resignation of Anne Anderson as Independent Non-Executive DirectorOct 04Immutep Completes Patient Enrolment in Randomised Phase II of AIPAC-003 Trial in Metastatic Breast CancerOct 03Immutep Limited Announces New Data from Eftisarc-Neo Phase II Evaluating Novel Triple Combination Including Immutep's Efti in Soft Tissue SarcomaSep 19Immutep Limited Announces Positive Efficacy and Safety Results from the TACTI-003 Phase IIb Trial Evaluating Eftilagimod AlphaSep 16Immutep Limited Announces Late-Breaking Abstract in Head & Neck Cancer Selected for Oral Presentation at ESMO CongressAug 21Immutep Announces First Participant Dosed in Phase I Study of Imp761, A First in Class Agonist Lag-3 AntibodyAug 14Immutep Announces Successful Meeting with FDA on Phase III Design in Non-Small Cell Lung CancerJul 23Immutep Limited Receives Regulatory Clearance for Phase I Study of First-In-Class Lag-3 Agonist Antibody Designed to Treat Autoimmune DiseasesJul 17Immutep Reports Positive Results in First Line Head and Neck Squamous Cell Carcinoma Patients with Negative Pd-L1 ExpressionJul 12Immutep Limited Announces Clinical Collaboration with Msd to Evaluate Efti in Combination with Keytruda®? (Pembrolizumab) in Pivotal Phase Iii TrialJun 05Immutep Limited Presents Data from Safety Lead-In Phase of AIPAC-003 at ESMO Breast 2024May 16Immutep Limited Reports Positive Initial Clinical Data Reported from Efti Combined with Radiotherapy and Checkpoint Inhibitor from Phase II Trial in Soft Tissue SarcomaMay 03Immutep Limited Announces Positive Preliminary Topline Results from TACTI-003 Cohort BApr 27Immutep Limited Appoints Leading Research Institute to Conduct First-In-Human Phase I Study of IMP761Apr 20Immutep Limited Receives Positive Feedback from the Spanish Medicines Agency for Upcoming Tacti-004 Registrational Trial in Metastatic Non-Small Cell Lung CancerApr 17Immutep Limited Announces First Clinical Data from 90Mg Dosing of EftiMar 05Immutep Limited Announces First Patient Dosed in Trial Evaluating Efti and the Anti-PD-L1 Therapy BAVENCIO in Metastatic Urothelial CancerJan 05Immutep Limited Receives Constructive Regulatory Feedback on TACTI-004 Registrational Trial in Metastatic Non-Small Cell Lung CancerDec 21Immutep Limited Completes Enrollment in TACTI-003 Phase IIb Trial of Efti and KEYTRUDA(R) in First Line Metastatic or Recurrent Head and Neck Squamous Cell CarcinomaNov 10Immutep Announces New Biomarker Data from Tacti-002 Phase II in First Line Non-Small Cell Lung CancerNov 04Immutep Limited Reports Promising Clinical Data from Insight-003 Trial at ESMO Congress 2023Oct 25Immutep Limited Announces Excellent New Clinical Data from the TACTI-002 / KEYNOTE-798 Phase II Trial Evaluating Eftilagimod AlphaOct 23Immutep Limited Announces Commercial Manufacturing of Eftilagimod Alpha at 2000L Scale Granted Authorization for Clinical Trial UseSep 22Immutep Limited, Annual General Meeting, Oct 24, 2023Sep 08Immutep Limited Receives Positive Scientific Advice from Committee for Medicinal Products for Human Use of European Medicines Agency for Continued Development of Eftilagimod AlphaAug 03Immutep Limited Announces First Patient Dosed in Chemotherapy-Free Triple Combination Phase II Trial Targeting Soft Tissue SarcomaJul 29Immutep Limited Doses First Patient in AIPAC-003 Phase II/III Trial for Metastatic Breast CancerMay 26+ 1 more updateImmutep Limited Announces Efti in Combination with Pembrolizumab Achieves Excellent Initial Overall Survival Benefit in 1st Line Non-Small Cell Lung CancerMay 18Immutep Limited Receives Positive Feedback from FDA on Late-Stage Clinical Development of Eftilagimod Alpha in Non-Small Cell Lung CancerMay 17Immutep Reaches Enrolment Target for INSIGHT-003 Trial in 1st Line NSCLCFeb 07Immutep Limited Announces Update on INSIGHT-003 Trial in NSCLCFeb 06Immutep Limited Enrolls and Randomised over 50% of the Planned 154 Patients in the Tacti-003 Phase IIB TrialJan 04Immutep Limited Completes Safety Run-In Data Review of the First Six Patients from the Phase Ii Clinical Trial of Eftilagimod Alpha Treatment by Immune Modulation in COVID-19 DiseaseJan 28Immutep Limited Discontinues its Phase II Clinical Trial Evaluating an Anti-Lag3 Cell Depleting Monoclonal Antibody, GSK2831781Jan 22Immutep Limited Completes Recruitment of Head and Neck Cancer Patients of Phase II TACTI-002 StudyJan 08Immutep Limited Announces Executive ChangesJan 05Immutep Limited Plans to Increase the Efti Manufacturing ProcessDec 18Immutep Limited Announces Operational UpdateDec 17Immutep’s Chinese Partner EOC Pharma to Start Phase II Metastatic Breast Cancer StudyDec 12Immutep Reports Statistically Significant Survival Benefit for Key Patient Groups in the Ongoing Phase IIb AIPAC Study in Metastatic Breast CancerDec 10Immutep Limited announced that it expects to receive AUD 29.572005 million in fundingNov 21Immutep Limited Announces Expansion of TACTI-002 Collaboration TrialNov 19Immutep Limited Announces New Interim Data from Its Ongoing Phase II Tacti-002 StudyNov 10Immutep Limited to Present AIPAC Overall Survival Data at the San Antonio Breast Cancer Symposium 2020Oct 20Immutep Limited Announces Improving Results from Stage I of Phase II TACTI-002 StudySep 18+ 1 more update재무 상태 분석단기부채: PRRU.F 의 단기 자산 ( A$139.8M )이 단기 부채( A$47.0M ).장기 부채: PRRU.F의 단기 자산(A$139.8M)이 장기 부채(A$1.3M)를 초과합니다.부채/자본 비율 추이 및 분석부채 수준: PRRU.F 부채가 없습니다.부채 감소: PRRU.F는 5년 전 부채 대비 자본 비율이 15.6%였으나 현재 부채가 없습니다.대차대조표현금 보유 기간 분석과거에 평균적으로 손실을 기록해 온 기업의 경우, 최소 1년 이상의 현금 보유 기간이 있는지 평가합니다.안정적인 현금 활주로: PRRU.F 현재 무료 현금 흐름을 기준으로 1년 이상 충분한 현금 활주로를 보유하고 있습니다.예측 현금 활주로: PRRU.F 26.5 1.7 26.5 % 매년.건전한 기업 찾아보기7D1Y7D1Y7D1YPharmaceuticals-biotech 산업의 건실한 기업.View Dividend기업 분석 및 재무 데이터 상태데이터최종 업데이트 (UTC 시간)기업 분석2026/05/03 03:51종가2026/04/28 00:00수익2025/12/31연간 수익2025/06/30데이터 소스당사의 기업 분석에 사용되는 데이터는 S&P Global Market Intelligence LLC에서 제공됩니다. 아래 데이터는 이 보고서를 생성하기 위해 분석 모델에서 사용됩니다. 데이터는 정규화되므로 소스가 제공된 후 지연이 발생할 수 있습니다.패키지데이터기간미국 소스 예시 *기업 재무제표10년손익계산서현금흐름표대차대조표SEC 양식 10-KSEC 양식 10-Q분석가 컨센서스 추정치+3년재무 예측분석가 목표주가분석가 리서치 보고서Blue Matrix시장 가격30년주가배당, 분할 및 기타 조치ICE 시장 데이터SEC 양식 S-1지분 구조10년주요 주주내부자 거래SEC 양식 4SEC 양식 13D경영진10년리더십 팀이사회SEC 양식 10-KSEC 양식 DEF 14A주요 개발10년회사 공시SEC 양식 8-K* 미국 증권에 대한 예시이며, 비(非)미국 증권에는 해당 국가의 규제 서식 및 자료원을 사용합니다.별도로 명시되지 않는 한 모든 재무 데이터는 연간 기간을 기준으로 하지만 분기별로 업데이트됩니다. 이를 TTM(최근 12개월) 또는 LTM(지난 12개월) 데이터라고 합니다. 자세히 알아보기.분석 모델 및 스노우플레이크이 보고서를 생성하는 데 사용된 분석 모델에 대한 자세한 내용은 당사의 Github 페이지에서 확인하실 수 있습니다. 또한 보고서 활용 방법에 대한 가이드와 YouTube 튜토리얼도 제공합니다.Simply Wall St 분석 모델을 설계하고 구축한 세계적 수준의 팀에 대해 알아보세요.산업 및 섹터 지표산업 및 섹터 지표는 Simply Wall St가 6시간마다 계산하며, 프로세스에 대한 자세한 내용은 Github에서 확인할 수 있습니다.분석가 소스Immutep Limited는 14명의 분석가가 다루고 있습니다. 이 중 7명의 분석가가 우리 보고서에 입력 데이터로 사용되는 매출 또는 수익 추정치를 제출했습니다. 분석가의 제출 자료는 하루 종일 업데이트됩니다.분석가기관Melissa BensonBarrenjoey Markets Pty LimitedThomas WakimBell PotterDylan DupuisB. Riley Securities, Inc.11명의 분석가 더 보기
Immutep Limited Reports Progress From Phase I Study Of LAG-3 Agonist IMP761 For Autoimmune DiseasesMar 19
Immutep Limited Discontinues TACTI-004 Phase III Study in First Line NSCLC Following Futility AnalysisMar 13
Immutep Limited Achieves 50% Enrolment in Global TACTI-004 (KeyNOTE-F91) Phase III Trial in 1L NSCLCFeb 06
Immutep Limited Announces Strong Operational Progress in Global TACTI-004 (KEYNOTE-F91) Phase III and Enrolment Continues At Robust PaceDec 17
Immutep Limited to Present New Data from AIPAC-003 Phase II at the 2025 San Antonio Breast Cancer SymposiumDec 02
Primary Endpoint Met in EFTISARC-NEO Phase II Evaluating Neoadjuvant Efti in Soft Tissue Sarcoma and Data Presented At ESMO Congress 2025Oct 21
Immutep Limited Announces Update for Tacti-004 (Keynote-F91) Phase Iii Trial in First Line Non-Small Cell Lung CancerOct 09
Immutep Limited Announces Data from EFTISARC-NEO Phase II Evaluating Neoadjuvant Efti in Soft Tissue Sarcoma Accepted for Oral Presentation At CTOS 2025Sep 08
Immutep Limited Receives Positive Feedback from FDA on Late-Stage Clinical Development of Eftilagimod Alfa in Head and Neck Cancer with CPSAug 05
Immutep Limited to Present Pivotal TACTI-004 Trial in Progress Poster at the 2025 World Conference on Lung CancerJul 29
Immutep Limited Announces Positive Update from Phase I Study of IMP761, A First-In-Class LAG-3 Agonist Antibody for Autoimmune DiseasesJun 24
Immutep Limited's Efti with Radiotherapy & KEYTRUDA®? (Pembrolizumab) Meets Primary Endpoint in Phase Ii for Soft Tissue SarcomaMay 27
Immutep Limited's Efti with Keytruda (Pembrolizumab) & Chemotherapy Achieves High Response Rates in First-Line Non-Small Cell Lung CancerMay 15
Immutep Limited's Efti in Combination with KEYTRUDA®? (pembrolizumab) Drives Strong Overall Survival in Head and Neck Cancer with CPSMay 06
Immutep Limited Announces First Patient Dosed in TACTI-004 Phase III Trial in First Line Non-Small Cell Lung CancerMar 25
Immutep Limited to Present Pivotal TACTI-004 Trial in Progress Poster At the European Lung Cancer Congress 2025Mar 20
Immutep Limited Announces Patient Enrolment Complete in the Investigator-Initiated EFTISARC-NEO TrialJan 22
Immutep Limited and Monash University Announce First Publication Detailing How Human LAG-3 Binds to MHC Class IIDec 16
Immutep Limited Reports Promising New Data in Head and Neck Cancer At ESMO Immuno-Oncology 2024Dec 12
Immutep Limited Announces Initiation of TACTI-004 Phase III Trial in First Line Non-Small Cell Lung CancerDec 10
Immutep Completes Patient Enrolment in Randomised Phase II of AIPAC-003 Trial in Metastatic Breast CancerOct 03
Immutep Limited Announces New Data from Eftisarc-Neo Phase II Evaluating Novel Triple Combination Including Immutep's Efti in Soft Tissue SarcomaSep 19
Immutep Limited Announces Positive Efficacy and Safety Results from the TACTI-003 Phase IIb Trial Evaluating Eftilagimod AlphaSep 16
Immutep Limited Announces Late-Breaking Abstract in Head & Neck Cancer Selected for Oral Presentation at ESMO CongressAug 21
Immutep Announces First Participant Dosed in Phase I Study of Imp761, A First in Class Agonist Lag-3 AntibodyAug 14
Immutep Announces Successful Meeting with FDA on Phase III Design in Non-Small Cell Lung CancerJul 23
Immutep Limited Receives Regulatory Clearance for Phase I Study of First-In-Class Lag-3 Agonist Antibody Designed to Treat Autoimmune DiseasesJul 17
Immutep Reports Positive Results in First Line Head and Neck Squamous Cell Carcinoma Patients with Negative Pd-L1 ExpressionJul 12
Immutep Limited Announces Clinical Collaboration with Msd to Evaluate Efti in Combination with Keytruda®? (Pembrolizumab) in Pivotal Phase Iii TrialJun 05
Immutep Limited Reports Positive Initial Clinical Data Reported from Efti Combined with Radiotherapy and Checkpoint Inhibitor from Phase II Trial in Soft Tissue SarcomaMay 03
Immutep Limited Appoints Leading Research Institute to Conduct First-In-Human Phase I Study of IMP761Apr 20
Immutep Limited Receives Positive Feedback from the Spanish Medicines Agency for Upcoming Tacti-004 Registrational Trial in Metastatic Non-Small Cell Lung CancerApr 17
Immutep Limited Announces First Patient Dosed in Trial Evaluating Efti and the Anti-PD-L1 Therapy BAVENCIO in Metastatic Urothelial CancerJan 05
Immutep Limited Receives Constructive Regulatory Feedback on TACTI-004 Registrational Trial in Metastatic Non-Small Cell Lung CancerDec 21
Immutep Limited Completes Enrollment in TACTI-003 Phase IIb Trial of Efti and KEYTRUDA(R) in First Line Metastatic or Recurrent Head and Neck Squamous Cell CarcinomaNov 10
Immutep Announces New Biomarker Data from Tacti-002 Phase II in First Line Non-Small Cell Lung CancerNov 04
Immutep Limited Announces Excellent New Clinical Data from the TACTI-002 / KEYNOTE-798 Phase II Trial Evaluating Eftilagimod AlphaOct 23
Immutep Limited Announces Commercial Manufacturing of Eftilagimod Alpha at 2000L Scale Granted Authorization for Clinical Trial UseSep 22
Immutep Limited Receives Positive Scientific Advice from Committee for Medicinal Products for Human Use of European Medicines Agency for Continued Development of Eftilagimod AlphaAug 03
Immutep Limited Announces First Patient Dosed in Chemotherapy-Free Triple Combination Phase II Trial Targeting Soft Tissue SarcomaJul 29
Immutep Limited Doses First Patient in AIPAC-003 Phase II/III Trial for Metastatic Breast CancerMay 26+ 1 more update
Immutep Limited Announces Efti in Combination with Pembrolizumab Achieves Excellent Initial Overall Survival Benefit in 1st Line Non-Small Cell Lung CancerMay 18
Immutep Limited Receives Positive Feedback from FDA on Late-Stage Clinical Development of Eftilagimod Alpha in Non-Small Cell Lung CancerMay 17
Immutep Limited Enrolls and Randomised over 50% of the Planned 154 Patients in the Tacti-003 Phase IIB TrialJan 04
Immutep Limited Completes Safety Run-In Data Review of the First Six Patients from the Phase Ii Clinical Trial of Eftilagimod Alpha Treatment by Immune Modulation in COVID-19 DiseaseJan 28
Immutep Limited Discontinues its Phase II Clinical Trial Evaluating an Anti-Lag3 Cell Depleting Monoclonal Antibody, GSK2831781Jan 22
Immutep Limited Completes Recruitment of Head and Neck Cancer Patients of Phase II TACTI-002 StudyJan 08
Immutep Reports Statistically Significant Survival Benefit for Key Patient Groups in the Ongoing Phase IIb AIPAC Study in Metastatic Breast CancerDec 10
Immutep Limited to Present AIPAC Overall Survival Data at the San Antonio Breast Cancer Symposium 2020Oct 20
Immutep Limited Announces Improving Results from Stage I of Phase II TACTI-002 StudySep 18+ 1 more update